| Liu, Yunpeng |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
NCT04612673: A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC |
|
|
| Not yet recruiting | 2 | 33 | RoW | Sintilimab | China Medical University, China, Shengjing Hospital, The First People's Hospital of Jingzhou, The People's Hospital of Liaoning Province, Liaoning Cancer Hospital & Institute, Anshan Tumor Hospital, Benxi Cental Hospital, The Second Affiliated Hospital of Dalian Medical University, The First Affiliated Hospital of Dalian Medical University | Non-small Cell Lung Cancer | 06/22 | 12/22 | | |
NCT04443036: Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma |
|
|
| Recruiting | 2 | 44 | RoW | Albumin-Bound Paclitaxel, Paclitaxel (albumin-bound), Paclitaxel for injection(Albumin Bound), Toripalimab | China Medical University, China | Gastric Carcinoma | 12/22 | 12/23 | | |
NCT05461235: Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma |
|
|
| Not yet recruiting | 2 | 1 | NA | Pembrolizumab, Keytruda, Nivolumab, Opdivo, Sintilimab, Daboshu, Toripalimab, Tuoyi, Camrelizumab, Airuika, Tislelizumab, Baizean, NK-Cell or DC-Cell | China Medical University, China | PD-1 Antibody, DC-Cell, NK-Cell, Gastrointestinal Tumours | 07/25 | 12/25 | | |
| Recruiting | 1/2 | 51 | RoW | AST-3424 | Ascentawits Pharmaceuticals, Ltd | Advanced Solid Tumors, Hepatocellular Carcinoma | 11/25 | 11/25 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT04008511: Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 1/2 | 54 | RoW | Regorafenib, Stivarga, Capecitabine, Xeloda, Oxaliplatin, ELOXATIN® | China Medical University, China, Liaoning Tumor Hospital & Institute, The First People's Hospital of Jingzhou | Metastatic Colorectal Cancer | 03/23 | 03/24 | | |
NCT04934514: Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 97 | RoW | IAH0968, Gemcitabine, Cisplatin | SUNHO（China）BioPharmaceutical CO., Ltd. | Advanced Solid Tumor | 12/24 | 03/25 | | |
NCT06255262: Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer |
|
|
| Not yet recruiting | 1/2 | 30 | RoW | Surufatinib, SULANDA, HMPL-012, Durvalumab, IMFINZI | China Medical University, China | Biliary Tract Cancer | 10/25 | 12/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT05426811: Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients |
|
|
| Not yet recruiting | 1/2 | 50 | NA | Regorafenib, Stivarga, Raltitrexed, Sai wei jian | China Medical University, China, The People's Hospital of Liaoning Province, Anshan Tumor Hospital, The First Affiliated Hospital of Dalian Medical University, The Second Affiliated Hospital of Dalian Medical University, Benxi Cental Hospital | Regorafenib, Raltitrexed, Colorectal Neoplasms, Third-line Treatment | 07/25 | 12/25 | | |
NCT04673396: Phase I Clinical Study for Evaluation of Pharmacokinetic, Safety, Tolerance of Norcantharidin Lipid Microsphere for Injection in Patients With Solid Tumor |
|
|
| Recruiting | 1 | 36 | RoW | Norcantharidin Lipid Microsphere for Injection, Tolerance,and Pharmacokinetic study, Sodium Demethylcantharidate Injection, Comparative Pharmacokinetic Studies | Beijing Nuokangda Pharmaceutical Technology Co., Ltd. | Solid Tumor | 12/21 | 07/22 | | |
NCT05339321: Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC |
|
|
| Recruiting | 1 | 36 | RoW | SCG101, PD1/PD-L1 checkpoint inhibitor | Peking Union Medical College Hospital | Hepatocellular Carcinoma | 07/23 | 12/23 | | |
NCT02929290: Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC |
|
|
| Recruiting | 1 | 80 | RoW | BPI-9016M, No other name so far | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 11/24 | 11/24 | | |
FIRELIGHT, NCT06169202: A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients |
|
|
| Recruiting | N/A | 50 | RoW | fruquintinib, elunate, Irinotecan, kaiputuo, Capecitabine, xiluoda | China Medical University, China | Fruquintinib, Irinotecan, Capecitabine, Gastrointestinal Tumours | 04/25 | 06/25 | | |
NCT05993702: TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer |
|
|
| Not yet recruiting | N/A | 45 | NA | regorafenib, baiwange, fruquintinib, elunate | China Medical University, China | TAS 102, Regorafenib, Fruquintinib, Gastrointestinal Tumours | 06/24 | 06/25 | | |
